Division of Nephrology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
Center for Access & Delivery Research & Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, Iowa, USA.
Blood Purif. 2022;51(7):559-566. doi: 10.1159/000517232. Epub 2021 Sep 14.
Continuous renal replacement therapy (CRRT) is a form of dialysis used in critically ill patients, and has recently been associated with renal nonrecovery. Decreases in platelets following CRRT initiation are common and are associated with mortality, but associations with renal recovery are unclear. Our objective was to determine if platelet nadir or the degree of platelet decrease following CRRT initiation was associated with renal nonrecovery.
This is a secondary analysis of the Randomized Evaluation of Normal versus Augmented Level (RENAL) trial. Primary predictors were platelet nadir discretized by median value and percent platelet decrease following CRRT initiation, with cut points evaluated by decile from 30 to 60%. The 2 primary outcomes were time to RRT-independence and RRT-free days. Secondary outcomes were 28-day mortality, 90-day mortality, intensive care unit (ICU)-free, and hospital-free days.
Time to RRT independence censored for death was achieved less frequently in patients with low platelet nadir (hazard ratio [HR] 0.77, confidence interval [CI] 0.66-0.91) and in those with >50% platelet decrease (HR 0.84, CI 0.72-0.97). RRT-free days were lower in both low platelet nadir (odds ratio [OR] 0.94, CI 0.90-0.97) and >50% platelet decrease (OR 0.91, CI 0.88-0.95). These groups also had higher rates of 28- and 90-day mortality and fewer ICU-free and hospital-free days. Thrombocytopenia at CRRT initiation was also associated with renal nonrecovery, although the clinical effect was small.
Platelet nadir <100 × 103/µL and platelet decrease by >50% following CRRT initiation were both associated with lower rates of renal recovery. Further research is needed to evaluate mechanisms-linking platelet changes and renal nonrecovery in CRRT.
连续肾脏替代疗法(CRRT)是一种用于危重病患者的透析形式,最近与肾功能恢复不良有关。CRRT 启动后血小板减少很常见,与死亡率相关,但与肾功能恢复的关系尚不清楚。我们的目的是确定 CRRT 启动后血小板最低点或血小板减少程度是否与肾功能恢复不良有关。
这是 RENAL 试验的二次分析。主要预测因素是血小板最低点按中位数离散和 CRRT 启动后血小板减少的百分比,通过 30%至 60%的十分位数评估切点。主要结局是达到无肾脏替代治疗(RRT)独立时间和无 RRT 天数。次要结局是 28 天死亡率、90 天死亡率、重症监护病房(ICU)无天数和医院无天数。
血小板最低点较低的患者(危险比[HR]0.77,置信区间[CI]0.66-0.91)和血小板减少>50%的患者(HR 0.84,CI 0.72-0.97),达到无 RRT 独立的时间更短。血小板最低点较低(比值比[OR]0.94,CI 0.90-0.97)和血小板减少>50%(OR 0.91,CI 0.88-0.95)的患者,无 RRT 天数也较低。这两组的 28 天和 90 天死亡率较高,ICU 无天数和医院无天数较少。CRRT 启动时发生血小板减少症也与肾功能恢复不良有关,尽管临床效果较小。
CRRT 启动后血小板最低点<100×103/µL 和血小板减少>50%与较低的肾功能恢复率相关。需要进一步研究来评估血小板变化与 CRRT 中肾功能恢复不良之间的机制联系。